BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9587133)

  • 1. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant.
    Chadburn A; Chen JM; Hsu DT; Frizzera G; Cesarman E; Garrett TJ; Mears JG; Zangwill SD; Addonizio LJ; Michler RE; Knowles DM
    Cancer; 1998 May; 82(10):1978-87. PubMed ID: 9587133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p16/INK4a in posttransplantation lymphoproliferative disorders.
    Martin A; Baran-Marzak F; El Mansouri S; Legendre C; Leblond V; Charlotte F; Davi F; Canioni D; Raphaël M
    Am J Pathol; 2000 May; 156(5):1573-9. PubMed ID: 10793069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.
    Knowles DM; Cesarman E; Chadburn A; Frizzera G; Chen J; Rose EA; Michler RE
    Blood; 1995 Jan; 85(2):552-65. PubMed ID: 7812011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation lymphoproliferative disorders in Mexico: an aggressive clonal disease associated with Epstein-Barr virus type A.
    Quintanilla-Martínez L; Lome-Maldonado C; Schwarzmann F; Gredler E; Reyes E; Angeles-Angeles A; Fend F
    Mod Pathol; 1998 Feb; 11(2):200-8. PubMed ID: 9504692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome.
    Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
    Transplantation; 2004 Feb; 77(3):431-7. PubMed ID: 14966421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.
    Cesarman E; Chadburn A; Liu YF; Migliazza A; Dalla-Favera R; Knowles DM
    Blood; 1998 Oct; 92(7):2294-302. PubMed ID: 9746767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders.
    Scheinfeld AG; Nador RG; Cesarman E; Chadburn A; Knowles DM
    Am J Pathol; 1997 Sep; 151(3):805-12. PubMed ID: 9284829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
    Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.
    Oyama T; Yamamoto K; Asano N; Oshiro A; Suzuki R; Kagami Y; Morishima Y; Takeuchi K; Izumo T; Mori S; Ohshima K; Suzumiya J; Nakamura N; Abe M; Ichimura K; Sato Y; Yoshino T; Naoe T; Shimoyama Y; Kamiya Y; Kinoshita T; Nakamura S
    Clin Cancer Res; 2007 Sep; 13(17):5124-32. PubMed ID: 17785567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology of posttransplantation lymphoproliferative disorders.
    Chadburn A; Cesarman E; Knowles DM
    Semin Diagn Pathol; 1997 Feb; 14(1):15-26. PubMed ID: 9044506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
    Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
    Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution.
    Lucioni M; Capello D; Riboni R; Ippoliti G; Campana C; Bandiera L; Arcaini L; Rossi D; Cerri M; Dionigi P; Lazzarino M; Magrini U; Viganò M; Gaidano G; Paulli M
    Transplantation; 2006 Oct; 82(8):1013-23. PubMed ID: 17060848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.
    Cuellar-Rodriguez J; Avery RK; Lard M; Budev M; Gordon SM; Shrestha NK; van Duin D; Oethinger M; Mawhorter SD
    Clin Infect Dis; 2009 Sep; 49(5):710-6. PubMed ID: 19635026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoproliferative disorders and hematologic malignancies following organ transplantation.
    Ferry JA; Jacobson JO; Conti D; Delmonico F; Harris NL
    Mod Pathol; 1989 Nov; 2(6):583-92. PubMed ID: 2587566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
    García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
    Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features.
    Orazi A; Hromas RA; Neiman RS; Greiner TC; Lee CH; Rubin L; Haskins S; Heerema NA; Gharpure V; Abonour R; Srour EF; Cornetta K
    Am J Clin Pathol; 1997 Apr; 107(4):419-29. PubMed ID: 9124210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.